The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to Truist Securities analysts. Meanwhile, the FDA moves forward on having ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

Does this mean it's time to dump your Moderna shares? First, it's important to note that Moderna's difficult times may not be over.

Moderna logo is seen in Warsaw, Poland on April 9, 2025. (Photo by Jakub Porzycki/NurPhoto via Getty ... More NurPhoto via Getty Images Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40% share price gain in 2025.

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine called mNexspike, with some limits on who can get it.

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option.

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.